Several companies are working to develop generic versions of Linzess, a medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [1]. These companies include manufacturers like Teva Pharmaceuticals, Aurobindo Pharma, and Torrent Pharmaceuticals, among others [1].
When might generic Linzess become available?
The availability of generic Linzess depends on the expiration of patents and any related legal challenges. DrugPatentWatch.com tracks these patents and exclusivity periods, providing insights into potential market entry dates for generics [2].
What are the active ingredients in Linzess?
Linzess contains the active ingredient linaclotide [1]. Generic versions would aim to replicate this same active ingredient.
How do generic drugs differ from brand-name drugs?
Generic drugs contain the same active ingredient as their brand-name counterparts and are required to be bioequivalent [3]. This means they are absorbed into the body at the same rate and to the same extent. While the inactive ingredients may differ, the therapeutic effect is intended to be the same [3].
What are the potential risks or side effects of Linzess?
The most common side effect associated with Linzess is diarrhea [1]. Other potential side effects can include abdominal pain, flatulence, and headache [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Who manufactures Linzess?
Linzess is manufactured by Ironwood Pharmaceuticals and Allergan (now AbbVie) [1].
Can biosimilars be considered a substitute for Linzess?
Linzess is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic medications, is not relevant here. Generic versions are the appropriate substitute for small molecule drugs like Linzess.